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Abstract
Background—Civilian posttraumatic stress disorder (PTSD) and combat PTSD are major public 
health concerns. Although a number of psychosocial risk factors have been identified related to 
PTSD risk, there are no accepted, robust biological predictors that identify who will develop 
PTSD or who will respond to early intervention following trauma. We wished to examine whether 
genetic risk for PTSD can be mitigated with an early intervention.
Method—65 emergency department patients recruited in 2009–2010 at Grady Memorial Hospital 
in Atlanta, Georgia, who met criterion A of DSM-IV PTSD received either 3 sessions of an 
exposure intervention, beginning in the emergency department shortly after trauma exposure or 
assessment only. PTSD symptoms were assessed 4 and 12 weeks after trauma exposure. A 
composite additive risk score was derived from polymorphisms in 10 previously identified genes 
associated with stress-response (ADCYAP1R1, COMT, CRHR1, DBH, DRD2, FAAH, FKBP5, 
NPY, NTRK2, and PCLO), and gene x treatment effects were examined. The intervention included 
3 sessions of imaginal exposure to the trauma memory and additional exposure homework. The 
primary outcome measure was the PTSD Symptom Scale-Interview Version or DSM-IV–based 
PTSD diagnosis in patients related to genotype and treatment group.
Results—A gene x intervention x time effect was detected for individual polymorphisms, in 
particular the PACAP receptor, ADCYAP1R1, as well as with a combined genotype risk score 
created from independent SNP markers. Subjects who did not receive treatment had higher 
symptoms than those who received intervention. Furthermore, subjects with the “risk” genotypes 
who did not receive intervention had higher PTSD symptoms compared to those with the “low-
risk” or “resilience” genotypes or those who received intervention. Additionally, PTSD symptoms 
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correlated with level of genetic risk at week 12 (P < .005) in the assessment-only group, but with 
no relationship in the intervention group, even after controlling for age, sex, race, education, 
income, and childhood trauma. Using logistic regression, the number of risk alleles was 
significantly associated with likelihood of PTSD diagnosis at week 12 (P < .05).
Conclusions—This pilot prospective study suggests that combined genetic variants may serve 
to predict those most at risk for developing PTSD following trauma. A psychotherapeutic 
intervention initiated in the emergency department within hours of the trauma may mitigate this 
risk. The role of genetic predictors of risk and resilience should be further evaluated in larger, 
prospective intervention and prevention trials.
Trial Registration—ClinicalTrials.gov identifier: NCT00895518
Unlike for other psychiatric disorders, the precipitant for posttraumatic stress disorder 
(PTSD) is a known event, allowing for immediate intervention with the potential to prevent 
PTSD’s occurrence. Currently, there are limited treatments to prevent PTSD in the acute 
aftermath of a trauma. One recently reported promising intervention1 compared an 
immediate intervention to assessment only in emergency department patients presenting 
after a DSM-IV criterion A traumatic event. The immediate intervention was aimed at 
preventing the development of PTSD and utilized components of prolonged exposure (PE), 
an empirically supported treatment for chronic PTSD that has not been tested immediately 
after trauma exposure. Results of this study indicated that the early intervention was 
effective at reducing the severity of reactions in those receiving the intervention compared to 
the control group.1 While identifying an intervention that can effectively prevent PTSD 
represents important progress, many individuals exposed to traumatic events will recover 
spontaneously and may not require intervention.2 An important goal of future research 
should be to determine who is at high risk for developing chronic PTSD so that efficacious 
interventions can be applied in a targeted fashion.3
Many research studies have sought to identify predictors of PTSD, including 2 meta-
analyses4,5 that identified significant risk factors for PTSD such as prior trauma, family 
psychiatric history, peritraumatic emotionality and dissociation, and posttrauma life stress 
and social support. While these findings are important to attend to, it is difficult to identify 
which patients need early intervention and which will recover naturally. Furthermore, the 
components of posttraumatic life stress and social support generally cannot be determined 
prospectively at the time of trauma. Even more importantly, none of these risk factors were 
necessary or sufficient in consistently predicting who will develop PTSD following trauma 
exposure. More recent work has broadened the possible risk factors and performed factor 
analytic approaches to obtain overall risk indices,6–8 but further work remains important in 
the area of prediction of PTSD following trauma exposure.
Better understanding of the mechanisms involved in predicting PTSD development is 
greatly needed. One area of great promise is the role of genetic biomarkers that may 
influence how an individual responds to and copes with trauma exposure. Research suggests 
that genetic factors account for approximately one-third of the overall risk for developing 
PTSD following exposure to traumatic events.9–11 This overall genetic risk is likely 
accounted for by many genetic markers, each carrying a small effect size. Several studies 
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have demonstrated, for instance, a gene-environment interaction whereby several single-
nucleotide polymorphisms (SNPs) of the FKBP5 gene interact with severity of child abuse 
to predict adult PTSD symptoms.12–16 Other research has identified higher concentrations of 
corticotropin-releasing factor (CRF), an important influence on responses to acute and 
chronic stress, among patients with PTSD.17 Specific polymorphisms within the 
corticotropin-releasing hormone type 1 receptor gene (CRHR1) have been shown to interact 
with a history of child abuse in predicting depression symptoms in adulthood,18 and 
prospectively to predict acute PTSD symptoms among pediatric injury patients.19 A recent 
study identified a sex-specific association between the function of the pituitary adenylate 
cyclase–activating polypeptide (PACAP) receptor (ADCYAP1R1) and abnormal stress 
responses underlying PTSD.20
These findings of genetic biomarkers of PTSD risk have great potential not only in 
advancing our understanding of the neurobiological underpinnings of PTSD, but also in 
improving our ability to provide early intervention to trauma-exposed individuals who are at 
highest risk for developing chronic PTSD. No research to date has examined the influence of 
genetic risk factors on response to early intervention for PTSD in the immediate aftermath 
of a traumatic event.
The objectives of this study were first to determine the effect of our prior identified PTSD-
related risk ADCYAP1R1 polymorphism in a separate, prospective study, and second, to 
examine whether response to an immediate exposure intervention would be associated with 
a combined potential “genetic risk score” across a number of formerly individually 
identified genes (ADCYAP1R1, COMT, CRHR1, DBH, DRD2, FAAH, FKBP5, NPY, 
NTRK2, and PCLO). We predicted that immediate psychotherapeutic intervention would 




A detailed description of the original study design has been reported previously.1 Eligible 
civilian patients presenting to the emergency department of the Grady Memorial Hospital in 
Atlanta, Georgia, following a DSM-IV criterion A trauma completed an initial assessment 
soon after the index trauma (mean = 11.8 hours, median = 6.92). Patients were randomly 
assigned to receive a modified PE intervention in the emergency department or assessment 
only. Patients separately consented to provide for DNA analysis a saliva sample that was 
collected during the initial assessment. Participants returned for follow-up at 4 and 12 weeks 
after trauma and were assessed for symptoms of PTSD. The study was approved by the 
university institutional review board and the hospital research oversight committee. The 
study was registered with ClinicalTrials.gov as “Examining the Effectiveness of an Early 
Psychological Intervention to Prevent Post-Traumatic Stress Disorder,” NCT00895518.
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Participants were recruited from the emergency department of an inner city level I trauma 
center. This trauma center is the largest in the state, and one of the largest in the United 
States, treating > 100,000 patients annually.
Participant Sample
Of 137 patients who agreed to participate in the original study, salivary DNA was obtained 
from 94 subjects, of whom 65 (34 assessment only, 31 intervention) completed the 12-week 
follow-up assessment. Data were available for 62 subjects for the first analysis and 65 
subjects for the remaining 12-week analyses. Table 1 contains demographic characteristics 
of the assessment and intervention participants. No differences in demographics or baseline 
measures were detected between the completer subsample of patients who provided a saliva 
sample and the total original sample.
Intervention
Therapists were trained in PE1,21 and also in the modified PE protocol. Therapists had a 
master’s or doctoral degree in psychology or social work. Patients received 3 hour-long 
sessions of a modified PE intervention distributed 1 week apart. See Table 1 of Rothbaum et 
al1 for a detailed description of the intervention. At both follow-up sessions, approximately 
85% of participants were compliant with all homework assignments, or were missing only 1 
component. Blinded assessors administered the PTSD Symptom Scale-Interview Version 
(PSS-I)22 and the Posttraumatic Stress Diagnostic Scale (PDS)23 at 4 and 12 weeks 
following enrollment in the emergency department. Approximately 88% of 4-week follow-
ups and 84% of 12-week follow-ups were conducted in person. In cases where a participant 
was unable to return for follow-up in person, the option to conduct the interview by phone 
was offered to minimize missing data. Patients meeting DSM-IV criteria for PTSD at the 3-
month follow-up were offered the full 9-session PE treatment1,21 at no charge.
Measures
Childhood Trauma Questionnaire (CTQ)—This self-report measure includes 28 items 
rated on a 1–5 scale (1 = never true, 5 = always true) and screens for 5 categories of 
childhood maltreatment: emotional neglect, emotional abuse, physical neglect, physical 
abuse, and sexual abuse.24 The CTQ has excellent psychometric properties.25–27
PTSD Symptom Scale-Interview Version (PSS-I).22—This semistructured interview 
consists of 17 items directly corresponding to the DSM-IV PTSD symptoms. Symptoms are 
rated by a clinician on a 0–3 scale (0 = not at all, 3 = 5 or more times per week/very much). 
The PSS-I has excellent psychometric properties and shows moderate to high agreement 
with the Structured Clinical Interview for DSM-IV Axis I Disorders and the Clinician-
Administered PTSD Scale for DSM-IV.28 In the current study, interrater agreement was 
0.99.
Posttraumatic Diagnostic Scale (PDS).23—The PDS is a 49-item self-report measure 
to assess severity of PTSD symptoms related to a single identified traumatic event. In this 
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study, the PDS was used at the time of the emergency department assessment to determine 
the subject’s PTSD symptoms from traumas prior to the index trauma for which they 
presented.
Genetics Methods
DNA was extracted from saliva collected in Oragene tubes (DNA Genotek, Inc, Ontario 
Canada) using the Agencourt DNAdvance isolation kit (Beckman Coulter, Inc, Brea, 
California). DNA samples were normalized to a concentration of 10 ng/μL then plated and 
dried in a polymerase chain reaction (PCR) plate at 20 ng. Multiplex PCR followed by 
single base extensions at each SNP was performed using Sequenom iPlex chemistries 
(Sequenom, Inc, San Diego, California), followed by mass spectrometry using the 
Sequenom MassArray.
For quality control measures, each DNA sample was extracted and genotyped in duplicate at 
separate time points, with multiple quality controls. Call rates exceeded 95% for all SNP 
assays. All SNPs passed Hardy Weinberg equilibrium (HWE) at P > .01 (corrected for 
multiple testing) for African Americans only (shown in Table 2). Note that in this small 
cohort, the ADCYAP1R1 SNP was at a trend significant level when corrected for multiple 
testing (P = .04); however, with larger sample sizes this SNP has consistently been found to 
be in HWE.
Sequenom MassArray technology was used to analyze a panel of 32 previously identified 
psychiatry-relevant SNPs representing 23 genes within 1 multiplex, 10 of which had 
previously been associated with PTSD or depression in traumatized populations. We 
focused on these 10 SNPs for this multigenic analysis. One SNP was chosen (due to its prior 
association with PTSD or its prior robust association with other psychiatric disorders in 
addition to its individual P < .05 association with PTSD within this dataset) from each of 
these 10 genes to be examined together within this analysis (Table 2).
Data Analysis
Throughout these analyses we either examined main effects of genotype on PTSD diagnosis 
(categorical based on DSM-IV from PSS interview), or we used continuous PTSD symptom 
scores with a dominant/recessive model for the SNPs examined. All included subjects had 
been exposed to a criterion A trauma. Data were examined with SPSS Statistics software 
(Version 20; IBM Corporation, Armonk, New York) using general linear model for 
treatment × genotype interactions and split either by treatment group or by defined genotype 
risk, followed by univariate ANOVA, bivariate correlations, and linear regression for 
continuous outcomes, and χ2 statistics and logistic regression for categorical outcomes. All 
analyses used 2-tailed tests.
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Summary of Study Patients
Of the 65 participants who completed the 12-week assessment and for whom we had genetic 
data, 54 (83.1%) were African American, 40 (61.5%) were female, and the mean age was 
33.0 years (SD = 11.6). See Table 1 for more details.
ADCYAP1R1, Genetic Risk, and Intervention Effects
We first examined the genotype of the PACAP receptor (ADCYAP1R1) allele that we 
previously found to be associated with PTSD (rs2267735, CC genotype)20 for its effect on 
PTSD symptoms at 4 and 12 weeks following the index trauma in intervention and 
assessment groups. We identified a gene × intervention × time-of-analyses effect (Figure 1, 
repeated measures ANOVA, 3-way interaction: F1,62 = 5.48, P < .02). For participants in the 
assessment group, those who were carriers of homozygous risk (CC) allele (PSS-I12-week 
[CC] = 27.83; 95% CI, 17.89 to 37.78) had higher levels of PTSD symptoms (PSS-I scores 
> 25) than those who were not (G-carriers), at week 12 (PSS-I12-week [G] = 16.32; 95% CI, 
11.13 to 21.51). In contrast, for participants in the intervention group, we found no 
difference in PSS-I scores across those with risk genotype status (PSS-I12-week [CC] = 
16.40; 95% CI, 8.70 to 24.10) and those without (PSS-I12-week [G] = 16.88; 95% CI, 10.98 
to 22.79). There were no significant differences at the 4-week time point for the intervention 
(P = .22) and the assessment groups (P = .32). Given that the initial report of rs2267735 was 
in females, it is important to note that the above findings hold when sex and race are 
included as covariates.
In addition to the association of ADCYAP1R1 on continuous PTSD symptoms, we examined 
whether the risk genotype was associated with PSS-I–based diagnosis of PTSD at week 12. 
Subjects with the risk genotype (CC) were more likely to be diagnosed with PTSD at week 
12 (87.5%) compared to carriers of the low-risk allele (12.5%) if they were assessed-only 
(χ21 = 5.85, P = .02), whereas there was no difference between genotype risk groups in the 
intervention cohort (χ2 = 0.04, P = .84).
Multigenotype Risk and PTSD Symptoms
We next assessed whether a combination of genes previously associated with PTSD and 
other stress-related disorders would provide more power to detect risk versus resilience 
following a trauma. Ten SNPs from 10 different genes were selected from previously 
published data on the basis of association with PTSD and other stress-related disorders (see 
Table 2). Using these 10 genotypes, we defined for each subject a genetic risk score of 0–10 
based on the number of homozygous risk genotypes. Notably, the direction of the risk 
variants utilized in the combined risk analyses was determined based on (1) their prior 
association with PTSD or (2) their prior robust association with other psychiatric disorders 
in addition to their individual P < .05 association with PTSD within this dataset. Seven 
genes were associated in the same direction as previously reported in PTSD and fear- or 
stress-related phenotypes (ADCYAP1R1, FKBP5, CRHR1, DBH, DRD2, NPY, and NTRK2). 
However, several genes appeared to be associated with risk in the opposite direction as 
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previously reported (COMT, FAAH, and PCLO), which may be related to both the differing 
racial makeup of our sample as well as different stress-related phenotypes.
We then examined whether the level of putative genetic risk from these 10 markers would 
associate with PTSD symptoms at 12 weeks, and we found effects similar, but more robust, 
to those above with a single gene. We first examined whether there was a relationship 
between level of multigentotype risk and PSS-I symptoms in assessed groups versus 
intervention groups. Whereas there was no relationship in the intervention groups (Figure 2: 
PSS-I12-week: r < −0.01, P > .5), there were significant positive relationships between 
genetic risk and total PSS-I symptoms in the assessment group (Figure 2: PSS-I12-week: r = 
0.55, P < .005). Of note, although we did not see the week-4 effect with the ADCYAP1R1 
gene alone, when using the genetic risk score, we did find a similar positive relationship 
between genetic risk and total PSS-I symptoms in the assessment group (PSS-I4-week: r = 
0.36, P < .05), but not in the intervention group (PSS-I12-week: r = 0.09, P > .5).
This relationship held across all 3 subscales of PTSD symptoms assessed at week 12 
(Reexperiencing: r = 0.49, P < .01; Avoidance: r = 0.46, P < .01; Hyperarousal: r = 0.52, P 
= .003). In contrast, there were no significant relationships between number of risk 
homozygous genotypes with any subscales in the intervention group. The 4-week measure 
demonstrated an effect of Reexperiencing (PSS-I4-week: r = 0.44, P < .01), but again, no 
differences were found in the intervention group.
We also performed a logistic regression analysis in which the continuous variable of number 
of high-risk alleles (0–10) was used to predict PTSD diagnosis (based on PSS-I) at week 12. 
We found that number of risk alleles was significantly associated with the likelihood of 
PTSD diagnosis (OR = 1.53; 95% CI, 1.06 to 2.02).
Multigenotype Risk Effects
Survive Regression Analyses—Due to the limited sample size, all of the preceding 
analyses were performed by examining main effects of genotype and treatment not including 
any covariates. To ensure that other factors associated with PTSD symptom risk were not 
driving the genetic or intervention effects found, a linear regression analysis was next 
performed in 4 steps, examining the effect of the multigenotype risk after controlling for 
effects of age, sex, race, education, income, and childhood trauma levels on PTSD 
symptoms at week 12. As with the above analyses, there was no association of genotype risk 
with PTSD symptoms in the intervention group. In contrast, in the assessment group, 
multigenotype risk was still associated with PTSD symptoms at week 12, when controlling 
for these other risk factors (Table 3; P = .026).
DISCUSSION
The current findings extend earlier work that genetic risk contributes to the relationship 
between exposure to traumatic events and the development of PTSD. More importantly, 
here we report that this risk may be mitigated by an early intervention. Our initial analyses 
showed that immediately following a traumatic event, survivors seeking medical care for 
their injuries were found to be at risk for increased PTSD symptoms 12 weeks after trauma 
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if they had the risk allele of the rs2267735 SNP from the PACAP receptor. These data 
suggest that in the absence of intervention, the prior association of the PACAP receptor and 
PTSD20 is replicated in a prospective study of traumatized civilians, as it has been similarly 
replicated in other cohorts49–51 (but also see Chang et al52). The administration of an 
immediate therapeutic intervention following the index trauma appears to mitigate this effect 
in the treatment group. Further analyses found that this same relationship was even more 
robust when we examined the combined risk genotypes outlined in Table 2.
A 1-hour exposure-based intervention administered first in the emergency department, and 
then again 1 and 2 weeks later, for a total of 3 sessions, was associated with significantly 
fewer symptoms at 12 weeks in those with the risk genotypes compared to those with the 
risk genotypes who received assessment only. Overall, patients with the low-risk genotypes 
fared well in both the assessment and intervention groups. Symptoms appeared to be 
cumulative (ie, more risk genotypes, more PTSD) for those in the assessment group, but not 
for those in the intervention group. The multigenotype risk predicted PTSD severity at week 
12 in the assessment group, but not in the intervention group. The presence of therapeutic 
intervention following the index trauma appears to mitigate the effect of genetic risk in the 
treatment group.
These results have meaningful clinical implications. Approximately 70% of individuals will 
undergo a potentially traumatic event in their lifetimes.53 Interventions can be costly, time 
consuming, and not necessary in all cases. If those at greatest risk can be identified and 
offered a brief intervention commencing before the memory is fully consolidated,54,55 the 
risk of that exposure may be mitigated. It is important to note that in this pilot trial a large 
percentage of patients seen in the emergency department were ineligible for enrollment,56 
and that 65%–70% were seen at the 12-week follow-up, which is less than the 70%–80% 
follow-up rates that have been seen in some other acute medical injury PTSD intervention 
trials. As previously discussed, it is important that broad generalizations are not made based 
on this pilot study from small, select samples.57 Finally, future studies with improved 
sampling and follow-up rates, as have been attained by Cunningham and colleagues,58,59 are 
indicated.
It is important to consider whether identifying genetic biomarkers is realistic in an 
emergency department setting and whether such biomarkers can be readily interfaced with 
implementable electronic medical record databases that are already being examined in 
population-level screening to identify those at risk for PTSD. Our current study does not 
address these issues, and it is important to treat these results as pilot findings suggesting that 
such polygenic factors may eventually be powerful additional biomarkers to consider. 
Although it is not currently routine to examine genetic data in emergency department 
settings, the technology clearly exists, as a number of rapid PCR-based tests are routinely 
used in primary and emergency department settings for other diagnostic approaches. As the 
era of personalized medicine continues to expand, it is quite likely that rapid, inexpensive 
genetic tests will be introduced for some aspects of biomarker-based risk across medical 
disciplines.
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Some strengths of this research include prospective screening and entering of high-risk 
patients presenting at a level I trauma center, innovative early intervention administered 
commencing in the emergency department, assessment and follow-up at time points when 
PTSD could be diagnosed, blind assessment, and rational exploration of the most promising 
genes for conferring risk. Limitations of this study include a small sample size for genetic 
research, lack of an attentional control group, utilization of common SNP variants identified 
primarily from candidate and not whole-genome studies, post hoc decisions regarding which 
genes to study, and loss of approximately 25% of the sample for the genetic analysis. 
Additionally, the sample was ethnically heterogeneous, although our findings survived 
covariation for race, as described. Future studies should rely on larger, in-progress Genome 
Wide Association Studies for PTSD risk and prospectively determine genotype prior to 
treatment assignment, as well as examine larger and more varied samples.60
The SNPs selected here are a very small percentage of the likely large and varied genetic 
risk involved in stress-related disorders that have yet to be identified. However, these data 
serve as a proof-of-principle, that as we obtain biomarkers for psychiatric risk, we may be 
better able to understand, prevent, and treat stress-related disorders. Although this was a 
small, pilot intervention study, these data suggest that genetic markers may serve to stratify 
and predict those who are most at risk for developing PTSD in the aftermath of severe 
trauma. Importantly, we find that utilizing a psychotherapeutic intervention within hours of 
the trauma may be successful at mitigating this potential genetic risk.
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• Psychosocial factors are related to differential PTSD risk, but biological markers 
are also needed to predict who is most at-risk for PTSD following trauma and 
who would respond to early intervention.
• This pilot study suggests that combined genetic variants associate with increased 
risk for PTSD in a prospective emergency department cohort.
• A psychotherapeutic intervention initiated within hours of the index trauma may 
mitigate this genetic risk.
• Genetic risk markers should be further evaluated in larger prospective trials of 
PTSD.
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Figure 1. ADCYAP1R1 Is Associated With Higher PTSD Symptoms in the Assessment Group 
Only, Not the Intervention Group at Follow-Up
aPTSD symptoms (PSS-I total score) are graphed at the 4-week and 12-week follow-up time 
points after the index trauma as a function of assessment only vs intervention group as well 
as high-risk ADCYAP1R1 (CC) vs low-risk ADCYAP1R1 (GG, GC) genotypes. The number 
of subjects included in both 4- and 12-week assessment periods are as follows: assessment 
group, low-risk ADCYAP1R1 genotype (n = 25), high-risk genotype (n = 8); intervention 
group, low-risk genotype (n = 18), high-risk genotype (n = 11). There is a gene × 
intervention × time of analyses effect (repeated measures ANOVA, 3-way interaction: F1,62 
= 5.48, P < .05).
bThe data are shown for the week 12 time point, in which those who were carriers of 
homozygous risk (CC) allele had higher levels of PTSD symptoms than those who were not 
carriers (F1,34 = 5.6, P < .05) for the assessment group only.
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Figure 2. Number of Homozygous Risk Genotypes Are Correlated With Higher PTSD 
Symptoms in the Assessment Group but Not the Intervention Group at 12-Week Follow-Upa
aNumber of high-risk genotypes are graphed relative to PSS-I total score and subscale scores 
across assessment and intervention groups.
bReexperiencing subscale symptoms are correlated with number of high-risk genotypes in 
the assessment group (A, n = 30, r = 0.49, P = .007), but not in the intervention group (B, n 
= 28, r = 0.12, P > .5).
cAvoidance subscale symptoms are correlated with number of high-risk genotypes in the 
assessment group (C, n = 30, r = 0.46, P = .011), but not in the intervention group (D, n = 
28, r = −0.005, P > .5).
dHyperarousal subscale symptoms are correlated with number of high-risk genotypes in the 
assessment group (E, n = 30, r = 0.52, P = .003), but not in intervention group (F, n = 28, r = 
−0.06, P > .5).
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eTotal PSS-I symptoms are correlated with number of high-risk genotypes in the assessment 
group (G, n = 34, r = 0.55, P = .002), but not in the intervention group (H, n = 31, r = −0.03, 
P > .5).
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Table 1
Sample Demographic Information (N = 65 12-week completers with genotype data)
Demographics Intervention (n = 31) Assessment (n = 34)
ANOVAa
F, P Values
Men, n (%) 15 (48.4) 10 (29.4) F1,65 = 2.49, P = .12
Age, y, mean (SD) 31.3 (11.6) 34.7 (11.5) F1,65 = 1.39, P = .24
Ethnicity, n (%) F1,65 = 1.19, P = .28
 White 1 (3.2) 5 (14.7)
 African  American 26 (83.9) 28 (82.4)
 Native American 1 (3.2) 0 (0)
Other 3 (9.7) 1 (2.9)
Trauma type, n (%) F1,65 = 0.47, P = .50
 Rape 9 (29.0) 9 (26.5)
 Nonsexual assault 10 (32.3) 8 (23.5)
 Motor vehicle accident 10 (32.3) 14 (41.2)
 Other 2 (6.5) 3 (8.8)
a
One-way ANOVA is shown, comparing intervention to assessment group, for number of subjects in each analysis examining: sex, age, ethnicity, 
and trauma type, showing no differences between groups in these categories.
Abbreviation: ANOVA = analysis of variance.













Rothbaum et al. Page 18
Table 2
Genes Comprising the Multigenotype Risk
Gene SNP Risk Genotype HWE P Value References for SNP and Stress-Related Disorders
ADCYAP1R1 rs2267735 CC .04 Ressler et al, 201120
Jovanovic et al, 201229
COMT rs4680 GG .82 Boscarino et al, 201230
Amstadter et al, 200931
CRHR1 rs7209436 CC .76 Bradley et al, 200818
Polanczyk et al, 200932
Laucht et al, 201233
DBH rs1611115 CC .91 Cubells et al, 200034
Tang et al, 201035
Mustapić et al, 200736
DRD2 rs6277 TT .17 Huuhka et al, 200837
Jutras-Aswad et al, 201238
Huertas et al, 201039
FAAH rs324420 CC .79 Sipe et al, 200240
Monteleone et al, 201041
Gunduz-Cinar et al, 201242
FKBP5 rs1360780 TT .15 Binder et al, 200812
Xie et al, 201013
NPY rs16147 GG .95 Zhou et al, 200843
Amstadter et al, 201044
NTRK2 rs1867283 GG .96 Kohli et al, 201045
PCLO rs2522833 AA .34 Sullivan et al, 200946
Hek et al, 201047
Kuehner et al, 201148
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Table 3
Multigenotype Risk Is Associated With Increased PTSD Symptoms in the Assessment Group and Not the 
Intervention Group at Week 12a
Treatment
Model Summary Change Statistics
Modelb R2 R2 Change
F Change
P Value
Assessment 1 0.158 0.158 .222
2 0.276 0.118 .176
3 0.405 0.129 .040
4 0.533 0.128 .026
Intervention 1 0.299 0.299 .055
2 0.409 0.111 .195
3 0.517 0.107 .061
4 0.551 0.034 .273
a
Bolded values were significant at P < .05.
b
Model 1: age, sex, race. Model 2: age, sex, race, education, income. Model 3: age, sex, race, education, income, childhood trauma level 
(Childhood Trauma Questionnaire [CTQ]). Model 4: age, sex, race, education, income, childhood trauma level (CTQ), with combined genetic risk.
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